The U.S. Food and Drug Administration has granted accelerated approval to daraxonrasib, a new drug designed to treat advanced pancreatic cancer, according to multiple reports including La Nación and CNN en Español. The approval was announced on August 27, 2026, and the drug is developed by Revolution Medicines.
Daraxonrasib targets a specific genetic mutation commonly found in pancreatic tumors. In clinical trials, the drug nearly doubled patient survival rates compared to existing treatments, as reported by Clarin.com. The FDA's accelerated approval pathway allows earlier access to promising therapies for serious conditions where unmet medical needs exist.
Pancreatic cancer is among the most difficult malignancies to treat, with most patients diagnosed at advanced stages when surgical options are limited. The approval marks a significant step forward, though La Nación notes the drug's potential to "transform" pancreatic cancer treatment. The New York Times reports that this approval could be the first of many similar targeted therapies to emerge.
The accelerated approval is based on early trial data showing meaningful improvements in patient outcomes. Revolution Medicines will need to conduct confirmatory studies to verify the drug's clinical benefit, a standard requirement for FDA accelerated approvals. If those studies confirm the initial results, daraxonrasib could become a standard treatment option for eligible pancreatic cancer patients.
Observers will be watching for the results of the confirmatory trials and whether the drug's benefits extend to other cancer types with the same genetic mutation.
